Life sciences companies use real-world evidence (RWE) to make key decisions throughout a therapy’s life cycle — from research and development (R&D) to clinical trials to commercial operations. Pfizer and [...]
How we’ve conducted clinical trials in the past will not be sustainable in the future. Less than four percent of Americans participate in clinical studies; 30 percent of patients drop out; [...]
Clinical Research News’ Deb Borfitz published an article about the importance of leveraging SDOH data to improve clinical trial diversity based on an interview with Clarify Health CEO and co-founder, [...]
Clinical trial diversity is crucial as factors like age, ethnicity, race, and sex can significantly impact how people respond to medicines and vaccines. However, some communities have historically been underrepresented [...]
Market Access Interview Interviewer: Rachael Hellman Interviewee: Colin Taggart While pharma companies are continuously innovating internal processes and implementing novel technologies to gain efficiencies across R&D and commercial, one function [...]
New product expands Clarify’s Growth Solution for life sciences companies, delivering comprehensive real-world insights software for the acceleration of therapy commercialization Clarify Health, a leading cloud analytics and value-based payments [...]
The FDA’s latest draft guidance on diversity and inclusion in clinical trials Diversity within the US continues to grow, with four in 10 Americans identifying with a race or ethnic [...]
pGHD is a medical condition that affects a child’s puberty and physical development. Somatropin injections are used to treat pGHD, improve growth in childhood, and prevent or improve metabolic impairments [...]
Clarify Health published a real-world study assessing medication adherence among patients with heart disease caused by transthyretin amyloid cardiomyopathy (ATTR-CM). The study titled “Baseline Characteristics and Secondary Medication Adherence Patterns [...]
Life science and healthcare industry leaders met at the 2021 CNS Summit to reflect on how pharmaceutical companies can leverage analytics and real-world evidence (RWE) to advance inclusion and diversity [...]